Here's Part 1 of industry experts sharing their perspectives on new and exciting developments impacting the plant breeding ...

Colossal, values the Dallas-based startup at a staggering $10.2 billion. Besides making it the first startup founded in Texas ...

Colossal Biosciences, the world’s first company dedicated to bringing back animals from extinction, has secured $200 million ...

The company said Jan. 15 that it has raised $200 million in series C funding led by TWG Global, the investment firm headed by ...

In Episode 746 of Power Athlete Radio, Dr. Adeel Khan dives into cutting-edge advancements in regenerative medicine, focusing on induced pluripotent stem cells ...

Orna Therapeutics and Vertex will use lipid nanoparticle system to develop gene-editing therapies for people with SCD and TDT ...

A Mayo Clinic-led team of researchers is solving one of the most frustrating aspects of genetic cancer screening — results ...

The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...

The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...

Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing ...

Expects submission of EMPAVELI sNDA for C3G and primary IC-MPGN in early 2025; U.S. launch anticipated in 2H 2025, if approved Plans initiation of Phase 3 studies of pegcetacoplan in two additional ...

Synthego, a leading supplier of CRISPR solutions, has entered a strategic licensing agreement with global biopharmaceutical company AstraZeneca. This agreement grants Synthego a global license to ...